AFT Pharmaceuticals (ASX:AFP, NZE:AFT) agreed to progress its injectable iron deficiency therapy to phase three trials as part of a new deal with Belgian firm Hyloris Pharmaceuticals, according to Monday filings with the Australian and New Zealand bourses.
It completed phase 2b trials for the therapy. The terms of an original conditional agreement the firm first disclosed in October 2024, call for both parties to secure an exclusive global intellectual property license upon meeting pre-specified conditions.
Hyloris will oversee product formulation, manufacturing, and the coordination of commercialization in Europe. AFT will manage the clinical trials, execution, and commercialization outside Europe.
Phase three clinical trials involving around 1,000 patients will be conducted in the US, Europe, India, and China to investigate the product's efficacy and safety.
Its shares rose almost 1% in early trading on the New Zealand bourse.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。